MedTrace Logo

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

NCT03634007 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-10-17

No results posted yet for this study

Summary

This clinical trial is an open label, dose-ranging study designed to evaluate gene therapy to treat patients who are APOE4 homozygotes with clinical diagnosis varying from mild cognitive impairment due to Alzheimer's, mild dementia due to Alzheimer's disease, and moderate dementia due to Alzheimer's disease.

Conditions

  • Alzheimer Disease
  • Early Onset Alzheimer Disease

Interventions

BIOLOGICAL

LX1001

LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.

Sponsors & Collaborators

  • Alzheimer's Drug Discovery Foundation

    collaborator OTHER

  • Weill Medical College of Cornell University

    collaborator OTHER

  • Lexeo Therapeutics

    lead INDUSTRY

Principal Investigators

  • Lexeo Clinical Trials · Lexeo Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-06
Primary Completion
2024-11-07
Completion
2024-11-07
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03634007 on ClinicalTrials.gov